Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIPAC: IMP321 plus paclitaxel in hormone receptor-positive metastatic breast cancer
NL-OMON55556Phase 2Active, not recruiting
- Sponsor
- Immutep Limited
- Start
- Feb 2016
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eftilagimod alpha in breast cancer, sponsored by Immutep Limited. Started Feb 2016; status: active, not recruiting.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON55556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55556.